DaVita Announces Final Results Of Self-Tender Offer

On September 17, 2020 DAVITA INC. (NYSE: DVA) ("DaVita") a health care provider focused on transforming care delivery to improve quality of life for patients globally and one of the largest providers of kidney care services in the United States, reported the final results of its modified "Dutch auction" tender offer for up to $1.0 billion of its common stock at a price per share not less than $77.00 and not more than $88.00, which expired at 12:00 midnight, New York City time, at the end of the day on September 14, 2020 (Press release, DaVita, SEP 17, 2020, View Source [SID1234565332]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based on the final count by the depositary for the tender offer, a total of 7,981,679 shares of DaVita’s common stock were validly tendered and not validly withdrawn at or below the price of $88.00 per share. DaVita accepted all of these shares for purchase at a purchase price of $88.00 per share, for a total cost of $702,387,752, excluding fees and expenses related to the tender offer. The total of 7,981,679 shares accepted for payment represents approximately 6.5% of DaVita’s total outstanding common stock as of September 16, 2020. The depositary for the tender offer will promptly pay for the shares accepted for purchase pursuant to the tender offer. Payment for shares purchased will be made in cash, without interest, but subject to applicable withholding taxes.

DaVita will finance the share purchases in the tender offer with cash on hand.

The dealer manager for the tender offer was BofA Securities, Inc. Georgeson LLC served as the information agent for the tender offer and Computershare served as the depositary for the tender offer.

Marker Therapeutics to Present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

On September 17, 2020 Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that its President and Chief Executive Officer, Peter L. Hoang, will present at the upcoming Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22, 2020 (Press release, Marker Therapeutics, SEP 17, 2020, View Source;medtech-summit-301132782.html [SID1234565331]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CONFERENCE DETAILS

Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, Sept. 22, 2020
Time: 1:40-2:20 p.m. ET

Live webcasts of the presentation will be accessible from the Investors section of the company’s website at markertherapeutics.com and will be available for replay following the event.

Accuray Radixact® System with Synchrony® Technology Delivers Advanced Cancer Treatments at Multiple Hospitals in Japan

On September 17, 2020 Accuray Incorporated (NASDAQ: ARAY) reported that leading hospitals in Japan are using the Radixact System with the Synchrony Automatic, Real-time Motion Synchronization Technology1 to provide advanced cancer treatments to more patients throughout the country (Press release, Accuray, SEP 17, 2020, View Source [SID1234565330]). The addition of Synchrony to the Radixact System will enable the hospital teams to efficiently deliver highly accurate radiation dose to tumors that move as a result of bodily processes or patient movement, minimizing the amount of healthy tissue surrounding the tumors that are exposed to high-dose radiation, all while patients breathe naturally – no uncomfortable patient restraints or breath-hold techniques are required. Synchrony is the only technology using image guidance during radiation delivery to automatically synchronize radiation treatment in real-time with the movement of the tumor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Multiple sites in Japan are now using the Radixact System with Synchrony, including Takarazuka City Hospital in Hyogo, Japanese Red Cross Nagoya Daini Hospital in Aichi, and Kishiwada Tokushukai Hospital in Osaka. The Synchrony technology will enable the hospital teams to treat a wider range of cancer cases, faster and with less harm to patients. The Takarazuka City Hospital team treated the first Synchrony patient in Asia, and was also the first in the world to perform a liver treatment with the innovative technology.

Japanese Red Cross Nagoya Daini Hospital replaced an existing TomoTherapy System with the next-generation Radixact System. The hospital team, in partnership with Nagoya City University, led by Prof. Yuta Shibamoto, is using the system and the Synchrony technology to expand cancer treatment capabilities and help improve patients’ outcomes.

"Using the Radixact System with Synchrony real-time tracking technology, SBRT at our hospital can be performed more effectively in the lower lobes of the lung. Synchrony enables us to reduce radiation exposure to healthy lung tissues in the lower lobe, because we no longer have to expand the treatment field to encompass the entire volume of tumor movement. I can confidently recommend Radixact with Synchrony to our patients," said Chikao Sugie, M.D., Vice Director of Department of Radiology at Japanese Red Cross Nagoya Daini Hospital. "The introduction of the Radixact System with Synchrony allows us to decrease the irradiated lung volume, making the treatment less stressful and invasive for patients, while also reducing the procedural burden on our healthcare team. In the future, I would like to expand the indications for treatment using this technology to include liver SBRT, based on our positive experience with lung SBRT and boost irradiation of advanced lung tumors. Synchrony technology has increased the versatility of the system and achieved automated, ultra-precise radiation therapy, which brings exceptional value to us."

"We are very encouraged by the early adoption of our Synchrony and Radixact System technologies by customers in Japan, the country currently with the highest penetration of these innovative solutions in the world. We are proud to have the opportunity to partner with such enthusiastic clinical professionals to advance cancer care in Japan," said Suzanne Winter, chief commercial officer and senior vice president, R&D at Accuray. "Cancer is highly prevalent in the aging Japanese population. Synchrony for the Radixact System will provide clinicians with the technology they need to effectively and efficiently treat virtually any patient requiring radiation therapy. The combined technologies enable the delivery of radiation using a variety of methods — from image-guided intensity-modulated radiation therapy (IG-IMRT) to stereotactic body radiation therapy (SBRT) — to treat almost any tumor, even those that move, with precision, accuracy and unprecedented flexibility."

Reminder: Centene Corporation’s 2020 Third Quarter Financial Results Conference Call

On September 17, 2020 Centene Corporation (NYSE: CNC) reported that issued a reminder that it will release its 2020 third quarter financial results at approximately 6 a.m. (Eastern Time) on Tuesday, October 27, 2020, and host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results. Michael F. Neidorff, Chairman, President and Chief Executive Officer, and Jeffrey A. Schwaneke, Executive Vice President and Chief Financial Officer, of Centene Corporation will host the call (Press release, Centene , SEP 17, 2020, View Source [SID1234565329]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 0677783, to expedite caller registration; or via a live, audio webcast on the Company’s website at www.centene.com, under the Investors section.

A webcast replay will be available for on-demand listening shortly after the completion of the call for the next 12 months or until 11:59 p.m. (Eastern Time) on Tuesday, October 26, 2021, at the aforementioned URL. In addition, a digital audio playback will be available until 9 a.m. (Eastern Time) on Tuesday, November 3, 2020, by dialing 1-877-344-7529 in the U.S. and Canada, or +1-412-317-0088 from abroad, and entering access code 10147833.

CNS Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

On September 17, 2020 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, reported that CEO, John Climaco, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22nd, 2020 at 10:00 AM EDT (Press release, CNS Pharmaceuticals, SEP 17, 2020, View Source;medtech-summit-301132810.html [SID1234565328]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Date:

Tuesday, September 22nd, 2020

Time:

10:00 AM EDT

Link:

View Source

A replay of the presentation will be available on the Company’s website for 90 days following the event. Members of management will hold 1-on-1 virtual investor meetings at the conference. Investors attending the conference virtually who are interested in meeting with Company management should contact their Oppenheimer representatives.